文献速递白血病

儿童NUP98重排急性髓系白血病的临床遗传学特征与结局:32例单中心队列研究

Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.
PubMed 文献 · Br J Haematol · 2026-04-28

该单中心回顾性研究纳入2017-2025年32例NUP98重排儿童AML患者,中位年龄8.7岁,以NUP98::NSD1融合(68.8%)为主,常共突变FLT3-ITD(50%)和WT1(43.8%)。首次和第二次诱导后完全缓解率从53.1%升至87.5%;中位随访41.7个月,3年总生存率81.2%、无事件生存率62.8%、累积复发率28.1%。

要点

  • NUP98重排儿童AML以NUP98::NSD1融合为主,常伴FLT3-ITD和WT1共突变。
  • 第二次诱导后未达完全缓解是总生存的危险因素。
  • 移植前MRD阳性是移植亚组复发的危险因素,WT1突变是全队列复发的危险因素。

核心结论

  • NUP98重排儿童AML需要包括移植在内的强化治疗。
  • WT1突变和移植前MRD阳性是风险适应策略的关键预后标志。

研究设计与样本

  • 回顾性单中心队列研究,纳入2017-2025年32例儿童NUP98重排AML患者。

主要发现

  • 中位年龄8.7岁,NUP98::NSD1融合占68.8%,FLT3-ITD共突变占50%,WT1共突变占43.8%。
  • 首次诱导后完全缓解率53.1%,第二次诱导后升至87.5%。
  • 中位随访41.7个月,3年总生存率81.2%(95%CI 65.9%-96.5%),无事件生存率62.8%(95%CI 43.8%-81.8%),累积复发率28.1%(95%CI 12.9%-45.6%)。
  • 29例移植患者中,3年总生存率79.8%(95%CI 63.5%-96.1%),无事件生存率68.7%(95%CI 50.3%-87.1%),累积复发率26.0%(95%CI 11.1%-43.9%)。
  • 探索性多因素分析显示,第二次诱导后未达完全缓解是总生存的危险因素,WT1突变是全队列复发的危险因素,移植前MRD阳性是移植亚组复发的危险因素。

临床怎么用

  • 对NUP98重排儿童AML应采用强化疗并考虑移植。
  • 评估WT1突变状态和移植前MRD以指导风险分层。

局限性

  • 回顾性单中心设计,样本量仅32例。
  • 多因素分析为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NUP98 rearrangements define a high-risk, genetically heterogeneous subtype of paediatric acute myeloid leukaemia (AML), yet comprehensive clinicogenetic and survival data remain limited. This retrospective, single-centre study of 32 paediatric patients (2017-2025) found a median age of 8.7 years and predominance of the NUP98::NSD1 fusion (68.8%), frequently co-mutated with FLT3-ITD (50%) and WT1 (43.8%). Complete remission (CR) rates increased from 53.1% to 87.5% after first and second induction. With a median follow-up of 41.7 months, the estimated 3-year overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse (CIR) were 81.2% (95% confidence interval [CI], 65.9%-96.5%), 62.8% (95% CI, 43.8%-81.8%) and 28.1% (95% CI, 12.9%-45.6%), respectively; corresponding rates among the 29 transplanted patients were 79.8% (95% CI, 63.5%-96.1%), 68.7% (95% CI, 50.3%-87.1%) and 26.0% (95% CI, 11.1%-43.9%) respectively. Exploratory multivariate analysis identified failure to achieve CR after induction 2 as a risk factor for OS, WT1 mutation for relapse in the entire cohort and pretransplant minimal residual disease (MRD) positivity for relapse in the transplant subgroup. This confirms that NUP98-rearranged AML necessitates intensive therapy including transplant and highlights WT1 and pretransplant MRD as key prognostic markers for risk-adapted strategies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang ZX, Zhang L, Lu AD, et al. Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases. Br J Haematol. 2026. PMID: 42047313. doi:10.1111/bjh.70497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。